StockGuide AI
Track Stocks
EN RU ES
Illumina Inc.

Illumina Inc.

Price: 162.47

Company and Business Model

Illumina Inc. specializes in genomic sequencing and analysis, providing tools and services for genetic research and diagnostics. Its core products include sequencing systems, reagents, and software for data analysis. Major business segments encompass research and clinical applications, with primary revenue sources derived from sales of sequencing instruments and consumables, as well as service agreements. The company serves a diverse clientele, including academic institutions, pharmaceutical companies, and healthcare providers.

Investment Profile

The investment profile of Illumina Inc. is more aligned with growth investors, given its focus on innovation in genomic technology and potential for market expansion. The stock may appeal to those seeking long-term capital appreciation rather than immediate income, as it does not currently offer dividends. The company's recent performance indicates moderate volatility, suggesting a balanced approach may be prudent for investors.

Official website

Fundamental metrics (experimental)

EPS (TTM) — earnings per share for the last 12 months, $
5.54 OK
Revenue QoQ — quarter-over-quarter revenue growth
-5.9% ↓
EPS surprise
9.5% better than expected
20d volatility
2.3% stable
FMP / FinFeed data updated: 2026-06-09

Forecast impact

limited
Target Raised · Guggenheim · valid until 2026-07-01 · updated 2026-06-11
Target +10.8% target fill 90.3%
Reaction D5 -0.47% · D10 pending market trust
Impact Potential 0 · Risk 0 price close to target
Reco: Hold Potential: 64 Risk: 60 Updated: 2026-06-11 05:21
How recommendation works
Why AI thinks so:
Mixed performance; cautious outlook amid revenue decline.

Track in portfolio

Price chart

AI recommendation Analyst forecast Calendar event Positive signal Negative signal Neutral / update Hold / informational B My buy S My sell
AI recommendation changes
Date Before After Reason
2026-06-05 02:40 Buy Hold Weak fundamentals with mixed momentum signals.
2026-05-28 02:47 Hold Buy Strong momentum, but revenue decline raises concerns.
2026-05-08 15:03 — Hold Mixed momentum; fundamentals show some weakness.
Analyst forecasts
Date Analyst Action Target Price Then
2026-06-01 11:27 Guggenheim Target Raised 170 → 180 162.96
2026-05-14 20:23 RBC Capital Update — → 170 143.24
2026-05-14 09:05 Daiwa Rating Upgraded — → 155 145